At TCI, we support discovery in life sciences through our knowledge and expertise in organic small molecules. This issue covers our life science topics as follows:
Regenerative Medicine Related Reagents
In recent years, organoids have come to the forefront as a model for the application of human induced pluripotent stem cells (iPSCs) in regenerative medicine. Organoids are in-vitro 3D cultured cell aggregates derivable from both iPSCs as well as somatic stem cells which are not only capable of self-organization and long term self-renewal, but which also exhibit similar morphology and function to the tissues from which they were derived. This is achieved through the use of physical and biochemical cues, such as extracellular matrix components and niche factors, which are able to recapitulate cells' natural environment within living tissue. TCI has an extensive lineup of chemicals frequently used in both organoid culture and iPS generation/differentiation.
Epigenetic Research Reagents
Epigenetics is the study of acquired chemical modifications of DNA and nuclear histone proteins that do not alter the DNA sequence but regulate gene expression and other processes that occur during development, cell differentiation, and carcinogenesis. Among others, DNA methylation and histone modification are two well-researched physiological mechanisms of epigenetic change. TCI offers DNA methyltransferase inhibitors, histone deacetylase (HDAC) inhibitors, histone methylation modulators, methylated nucleosides, etc.
DOTA Derivatives as Chelating Agents for Radioisotopes
DOTA is a chelating agent which consists of a 12-membered ring containing nitrogen and can coordinate with various metal species. DOTA is widely used in PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) scans due to the high stability of its coordination compounds. Several DOTA derivatives are available such as azido-mono-amide-DOTA [A3478] with an azido group, DOTA-ADIBO [D6006] with an ADIBO group, and DOTA-NHS hexafluorophosphate trifluoroacetate [D6007] with an NHS group, allowing for quick and easy labeling of various probes.
Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors
The LRRK2 is a large protein (2527 amino acids) with serine-threonine (Ser/Thr) protein kinase activity and autophosphorylation activity. It is highly expressed in many mammal tissues. Genetic mutations in the G2019S encoding portion of LRRK2 (LRRK2-G2019S) have been detected frequently in Parkinson's (PD) patients. As a result, LRRK2-G2019S is a promising therapeutic target for the treatment of PD, and its inhibitors have been used as useful tools in PD research. TCI offers many LRRK2 inhibitors such as SP 600125 [A2548] and sorafenib [O0599].
Upcoming Events
» TCI eNewsletter Back Issues
